Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Lagercrantz Group in connection with the acquisition of Wapro AB
Mandate

Vinge advises Lagercrantz Group in connection with the acquisition of Wapro AB

July 07, 2017

Wapro AB develops, markets and sells innovative products which prevent and regulate water flow in order to protect properties and infrastructure from flooding during storms and seasonal high water level. 

Wapro’s head office is in Karlshamn, and it also has a subsidiary in Chicago, USA. Wapro’s turnover is approximately MSEK 40 with good profitability and the company conducts operations in, inter alia, Europe, North America and Australia.

Vinge’s team consisted of partners Johan Winnerblad and Kristina Ekberg together with, among others, associates Filip Öhrner and Manne Bergström.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024